RT Journal Article
SR Electronic
T1 Plasma Metabolomic and Lipidomic Alterations Associated with COVID-19
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.04.05.20053819
DO 10.1101/2020.04.05.20053819
A1 Wu, Di
A1 Shu, Ting
A1 Yang, Xiaobo
A1 Song, Jian-Xin
A1 Zhang, Mingliang
A1 Liu, Wen
A1 Huang, Muhan
A1 Yu, Yuan
A1 Yang, Qingyu
A1 Zhu, Tingju
A1 Xu, Jiqian
A1 Mu, Jingfang
A1 Wang, Yaxin
A1 Wang, Hong
A1 Tang, Tang
A1 Ren, Yujie
A1 Wu, Yongran
A1 Qiu, Yang
A1 Zhang, Ding-Yu
A1 Shang, You
A1 Zhou, Xi
YR 2020
UL http://medrxiv.org/content/early/2020/04/07/2020.04.05.20053819.abstract
AB The pandemic of the coronavirus disease 2019 (COVID-19) has become a global public health crisis. COVID-19 is marked by its rapid progression from mild to severe conditions, particularly in the absence of adequate medical care. However, the physiological changes associated with COVID-19 are barely understood. In this study, we performed untargeted metabolomic and lipidomic analyses of plasma from a cohort of COVID-19 patients who had experienced different symptoms. We found the metabolite and lipid alterations exhibit apparent correlation with the course of disease in these COVID-19 patients, indicating that the development of COVID-19 affected patient metabolism. Moreover, many of the metabolite and lipid alterations, particularly ones associated with hepatic functions, have been found to align with the progress and severity of COVID-19. This work provides valuable knowledge about blood biomarkers associated with COVID-19 and potential therapeutic targets, and presents important resource for further studies of COVID-19 pathogenesis.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the Strategic Priority Research Program of CAS (XDB29010300 to X.Z.), the National Science and Technology Major Project (2020ZX09201-001 to D.-Y.Z, and 2018ZX10101004 to X.Z.), and National Natural Science Foundation of China (81873964 to Y.Q., and 31670161 to X.Z.).Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are available from the authors upon request